Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that tests evaluated through the application process and/or technical assessment will be reviewed 
to answer the following questions: 
 
 Is the test performed in the absence of clinical signs and symptoms of disease? 
 Will the test results provide the clinician with information that will improve patient outcomes and/or change 
physician care and treatment of the patient? 
 Will the test results confirm a diagnosis or known information? 
 Is the test performed to determine risk for developing a disease or condition? 
 Will risk assessment change management of the patient? 
 Is there a diagnosis specific indication to perform the test? 
 Is the test performed to measure the quality of a process or for Quality Control/Quality Assurance (QC/QA), 
i.e., a test to ensure a tissue specimen matches the patient? 
 
MDT Policy Specific Definitions 
 
MDT: Any test that involves the detection or identification of nucleic acid(s) (DNA/RNA), proteins, 
chromosomes, enzymes, cancer chemotherapy sensitivity and/or other metabolite(s). The test may or may not 
include multiple components. A MDT may consist of a single mutation analysis/identification, and/or may or 
may not rely upon an algorithm or other form of data evaluation/derivation. 
 
Laboratory developed test (LDT): Any test developed by a laboratory developed without Food and Drug 
Administration (FDA) approval or clearance. 
 
Applicable Tests/Assays 
 
In addition to the MDT definition, this coverage policy applies to all tests that meet at least one of the 
following descriptions: 
 All non-FDA approved/cleared laboratory developed tests (LDT) 
 All modified FDA-approved/cleared kits/tests/assays 
 All tests/assays billed with more than one code from a HIPAA compliant code set to identify the service, 
including combinations of method-based, serology-based, and anatomic pathology codes 
 All tests that meet the first three bullets and are billed with a Not Otherwise Classified NOC code 
  Unique Test Identifier Requirement 
 
Because the available language in the current HIPAA compliant code sets used to describe the pathology and 
laboratory categories and the tests included in those categories are not specific to the actual test results 
provided, all MDT services must include an identifier as additional claim documentation. Test providers 
must receive an identifier specific to the applicable test and submit the test assigned identifier with the claim 
for reimbursement. The assigned identifier will provide a crosswalk between the tests associated detail 
information on file and the submitted claim detail line(s) required to adjudicate each tests claim. The unique 
identifier limits the need to submit the required additional information about the test on each claim. 
 
Technology Assessments (TA) 
 
MolDX will review all new test/assay clinical information to determine if a test meets Medicares reasonable 
and necessary requirement. Labs must submit a comprehensive dossier on each new test/assay prior to claim 
submission. MolDX will only cover and reimburse tests that demonstrate analytical and clinical validity, and 
clinical utility at a level that meets the Medicare reasonable and necessary requirement. 
 
Payment Rules 
 
MolDX will reimburse: 
 approved tests covered for dates of service consistent with the effective date of the coverage determination. 
 
You can find this information in the Local Coverage Determination (LCD) MolDX: Molecular Diagnostic 
Tests (MDT) L35160. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.